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rash, to $2,728 (78 days) for sleep-related symptoms and $4,434 (41 days) for nau-
sea/vomiting. Mean incremental cost per AE episode ranged from $1,581 (rash),
$2,033 (lipid disorders) to $12,834 (nausea/vomiting) and $22,321 (sleep-related).
CONCLUSIONS: Treatment-associated AEs are now essential considerations with
increased HIV patient longevity. In addition to clinical implications, economic
costs should be considered in NNRTI-containing treatment regimen decisions and
for estimating cost-effectiveness of therapy.
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OBJECTIVES:Drugs used in the treatment of Human Immunodeficiency Virus (HIV)
which form part of Highly Active Anti-retroviral Therapy (HAART) are usually ex-
pensive and may have serious side effects. The objective of this study was to
compare the costs and adverse events of a new therapeutic agent, Rilpivirine, with
an established agent, Efavirenz, used in the treatment of HIV, both of which form
part of HAART among treatment naïve patients.METHODS: Decision tree analysis
was used to compare the direct medical costs of using Rilpivirine versus Efavirenz
in HAART from the societal perspective. Drug costs were obtained from an online
drug information source and Red Book 2008. Base case probabilities of having an
adverse event were obtained from a published clinical trial comparing Rilpivirine
versus Efavirenz (N690). Costs for treating adverse events were obtained from the
Medical Expenditure Panel Survey Database (2008). All costs were converted into
2011 US dollars. Sensitivity analyses were performed to determine the effects of
variations in assumptions regarding drug costs and costs for treating adverse
events on study results. All analyses were conducted using the 2011 TreeAge Pro
Software. RESULTS: The analyses showed that Rilpivirine is the treatment of
choice in the first year of therapy with a net cost of $27,282 per patient for Rilpi-
virine as compared to $28,619 per patient for Efavirenz. These results were robust
to changes in assumptions about costs of adverse events. If the cost of Rilpivirine
was higher than $11,610 or if the cost of Efavirenz was lower than $6,387, Efavirenz
would be the treatment of choice. CONCLUSIONS: From a societal standpoint,
Rilpivirine as part of HAART costs less as compared to Efavirenz. Future studies
should aim at comparing Rilpivirine with other established drugs used in the treat-
ment of HIV.
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OBJECTIVES: To determine the incremental economic burden associated with
Clostridium-difficile associated diarrhea (CDAD) among patient sub-populations at
elevated risk for recurrent CDAD: immunocompromised (IC), prior CDAD, concur-
rent antibiotic use (cABx), renally impaired (RI), inflammatory bowel disease (IBD),
and age  65 years (elderly) patients. METHODS: CDAD cases hospitalized with a
diagnosis of CDAD (ICD-9-CM: 008.45) having 12 months of prior health plan
eligibility and 18 years of age between January 1, 2005 and October 31, 2010 were
identified from the HealthCore Integrated Research Database (HIRDSM). CDAD
cases within each sub-population were matched to hospitalized controls without
CDAD diagnosis based on: age10 years, gender, preceding/in-hospital comorbidi-
ties (cardiovascular, pulmonary, haematopoietic, and musculoskeletal) and use of
antibiotics. Incremental hospital length of stay (LOS) and hospital costs were cal-
culated betweenmatched cases and controls usingmultivariate generalized linear
models using a Gamma distribution. Covariates were determined frompost-match
univariate analysis of baseline characteristics for each sub-population. RESULTS:
Post-match case-to-control ratios ranged from 1:1 to 1:3 for each sub-population
(IC: n3,586 cases; prior CDAD: n933 cases; cABx: n4,429 cases; RI: n5,533
cases; IBD: n1,206 cases; elderly: n10,933 cases). Post-match comparisons of
baseline characteristics indicated no significant (P0.05) difference in targeted
match criteria. Compared to controls in all sub-populations, CDAD cases had sig-
nificantly greater (P0.0001) hospital LOS (mean incremental days [95% C.I.]; IC: 8.4
[7.9-9.0]; prior CDAD: 2.9 [2.4-3.6]; cABx: 7.8 [7.4-8.3]; RI: 17.3 [16.4-18.3]; IBD: 3.3
[2.9-3.7]; elderly: 7.8[7.5-8.1]) and hospital costs (mean incremental USD [95% C.I.];
IC: $31.8K [28.5-35.5]; prior CDAD: 28.0K [19.7-40.0]; cABx: 36.3K [33.3-39.6]; RI:
$115.6K [105.2-127.1]; IBD: $11.2K [9.3-13.4]; elderly: $43.2K [40.9-45.7]).
CONCLUSIONS: This study demonstrates the significant incremental economic
burden associated with CDAD both within the hospital setting and from a payer
perspective. CDAD patients in each sub-population incurred significantly greater
hospital LOS and corresponding hospital costs relative to matched controls.
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OBJECTIVES: Complicated skin and skin structure infection (cSSSI) is a common
and costly condition. Telavancin, a bactericidal lipoglycopeptide antibiotic, was
approved in September 2009 as a once-daily therapy for cSSSI. A retrospective
analysis was conducted using the Premier database to compare hospital resource
utilization and costs of cSSSI patients treated with telavancin or daptomycin.
METHODS: Adults with a hospital admission diagnosis of cSSSI receiving telavan-
cin or daptomycin during 2010 were selected. cSSSI was defined by 2011 IDSA
guidelines using ICD-9-CM codes. Logistic regression predicting treatment choice
and clinical opinion were used to identify thematched variables: age, gender, race,
primary diagnosis of cSSSI, prior MRSA infection, APR SOI score, hospital location
of drug initiation, and obesity. Eighty telavancin admissions were matched to 80
daptomycin admissions. Length of stay (LOS) in the hospital and ICU, and post-
drug LOS were analyzed. Costs were calculated using patient billing data. Unad-
justed regression models with gamma distribution and a log link were utilized.
RESULTS: The mean age was 54 years and 64% were male in both groups. Major
underlying conditions included MRSA infection (35 vs. 23%), sepsis (26 vs. 28%),
diabetes (23 vs. 35%), and/or obesity (16 vs. 16%) (telavancin vs. daptomycin, re-
spectively). Patients receiving telavancin had less LOS (11.9 vs. 14.8 days), post-drug
LOS (7.9 vs. 8.8 days), ICU-LOS (3.2 vs. 4.0 days), total hospital costs ($29,791 vs.
$39,054), and pharmacy costs ($4,918 vs. $8,366). Due to large variance in the data,
however, nonewere statistically significant. Total dosing of study drugswas higher
(4,450 mg vs. 3,061 mg) and daily cost was lower ($283 vs. $367) for telavancin
patients. CONCLUSIONS: For all categories, consistently lower resource utilization
and costs in the telavancin group compared to the daptomycin group were ob-
served, although differences were not statistically significant.
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OBJECTIVES: Staphylococcus aureus is a common cause of nosocomial infections in
acute care hospitals. This study aimed to estimate the clinical and economic im-
pact of S. aureus infections associated with surgical procedures in US hospitals.
METHODS: The analysis used the 2009 US National Inpatient Sample data, repre-
senting a 20% sample of 1050 hospitals from 44 states. The seven surgical sub-
groups examined included vascular, cardiothoracic, general, orthopedic, neurosur-
gical, plastic, and GYN/GU surgeries. S. aureus infection rates, length of stay, total
hospital charges and in-hospital mortality were estimated. Multivariate models
adjusted for sampling weights were used for analyses that control for age, gender,
race, payer source, comorbidities, procedure type, admission type and hospital
characteristics. RESULTS: In total, there were 6,894,989 hospitalizations that in-
volved at least 1 of the 7 surgical subgroups among patients age  18. Surgical S.
aureus infectionwas reported as a discharge diagnosis in 61,783 admissions, or 0.90
per 100 admissions (95% CI, 0.85-0.94). S. aureus infection rates varied largely by
surgical subgroups, ranging from 0.12% in GYN/GU to 5.42% in plastic procedures.
The adjusted excess length of stay associated with S. aureus infection was 9.5 days
compared to procedures with no S. aureus infection, ranging from 4.6 days in or-
thopedic procedures to 12.8 days in general procedures. The excess hospital charge
associated with S. aureus infection was also significant at the adjusted mean of
$67,939 compared to no infection. The inpatients with S. aureus infection had 2.1
(95% CI, 1.9-2.3) times the odds of dying in the hospital than patients without S.
aureus infection. CONCLUSIONS: The total number of inpatient S. aureus infections
and its clinical and economic impact on US hospitals were substantial. Prevention
of S. aureus infections would improve clinical outcomes and benefit hospitals and
society in terms of decreased use of scarce health care resources.
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OBJECTIVES: This study aimed to evaluate the costs and outcomes of hospital-
acquired blood stream infections.METHODS: This case control retrospective study
captured data on inpatients in the private hospital for a period of 2 years. The case
group had patients who had developed hospital acquired blood stream infections
and they were matched with controls on the basis of age, primary diagnosis, and
severity of illness. While all the costs were included, the outcome measures ad-
optedwere discharge status, length of stay andmortality of patients.RESULTS:The
results are based on 30matched patients in each arm.While hypertension was the
chief co-morbidity present in both the arms, upto 37% of the patients had none.
Staphylococci and Acinetobacter bauminii/hemolyticus were found to the most com-
mon pathogens, of the 15 identified responsible for causing hospital-acquired
blood stream infections. Polymixins were the most commonly used antimicrobial,
prescribed to 12 patients, followed by Teicoplanin and Linezolid. The 11/30 & 14/30
patients improved in the case and the control group, respectively. The total LOS
and the ICU LOS was significantly higher in the case group compared to controls.
The crudemortality rate for the casewas 53% against 23% for controls. Themedian
of the total cost of treatmentwas statistically significantly higher for the case group
when compared to the control (p0.001). Drug costs accounted for over 50% of the
total costs of treatment. CONCLUSIONS: These results confirm that hospital-ac-
quired blood stream infections pose an additional burden of the health resources &
significantly affect the mortality.
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